January 10, 2021
No Camels
Vancouver-based company SaNOtize, co-founded by Israeli-Canadian scientist Dr. Gilly Regev, is launching its first clinical trial in the UK this week for a proposed antiviral nasal spray for use against COVID-19.
The tests will begin on Monday at Ashford and St Peter’s Hospitals NHS Foundation Trust in Surrey and will be overseen by Rob Wilson, a former British government minister who represents SaNOtize in the UK and EU, the company announced in a statement Sunday.
September 29, 2020
Kelly Cutrara 640 Toronto – POD
The Kelly Cutrara Show: SaNOtize CEO Dr. Gilly Regev discussing human trials for anti-viral COVID treatment.
Canadian anti-viral COVID treatment is conducting human trials
August 5, 2020
DRISHTI
SaNOtize Research and Development Corporation, a biotech company based in Vancouver, is one of the agencies at the forefront of the efforts to prevent and treat COVID-19. This past May, SaNOtize announced that enrolment of its first participant in a multi-center Phase II trial of its patented Nitric Oxide Releasing Solution (NORS) for the prevention and early treatment of COVID-19.
June 22, 2020
BusinessWire- OurCrowd
Thousands of Investors From 90 Countries Attend OurCrowd Pandemic Innovation Conference Online, First Global Event Dedicated to Pandemic Investment: SaNOtize’s coronavirus therapy is pursuing clinical trials in the UK
June 5, 2020
My Healthy Click
Canadian biotech company SaNOtize Research is experimenting with nitric oxide through nasal spray or mouth gargles on those who are at a high risk of getting infected from COVID-19 in the first place.
Researchers Examine Nitric Oxide as an Experimental Treatment for COVID-19
June 3, 2020
BIV
Vancouver biotech and medical device companies have recently received government funding, inked partnerships with big pharmaceutical companies and gained quick regulatory approvals to move their platforms and discoveries to the front of the clinical trial queue.
June 2, 2020
Global News Morning Montreal
SaNOtize CEO Dr. Gilly Regev on Global News Montreal to discuss the company’s Montreal based clinical trial.
June 1, 2020
Headtopics
A clinical trial examining the use of nitric oxide as a treatment for COVID-19 has been expanded, as a Canadian company explores how its nasal spray might protect front-line workers and those suffering from the disease.
Could a simple gas produced by our bodies be used to treat COVID-19?
May 31, 2020
CTV News
SaNOtize Research has been given a $400,000 grant from the National Research Council and is now conducting phase two of a clinical trial on people at high risk for contracting COVID-19, including front-line workers, and those with mild symptoms of the disease.
Could a simple gas produced by our bodies be used to treat COVID-19? Canadian trials underway
May 26, 2020
iHeart Radio – CJAD 800
A Vancouver-based biotech company is looking for people in Montreal to take part in clinical trials for a potential new COVID-19 treatment.
The potential treatment from the firm SaNOtize uses a known anti-microbial called nitric oxide, and the company hopes it can be marketed as a preventative treatment against COVID-19 until a vaccine becomes available.
‘Like hand sanitizer for your nose’: potential COVID-19 treatment to be tested in Montreal“
May 25, 2020
CTV News Vancouver
SaNOtize featured on CTV News Vancouver
Like hand sanitizer for your nose: Vancouver scientists test new COVID treatment
Business Insider
SaNOtize Research and Development Corporation today announced it enrolled its first participant on May 12, 2020 in a multi-centre Phase II trial of its Nitric Oxide Releasing Solution (NORSTM) for the prevention and early treatment of COVID-19.
SaNOtize Phase II COVID Prevention and Treatment Trial Underway
May 6, 2020
Vancouver Sun
SaNOtize has Health Canada Phase 2 approval to test a nitric oxide antiviral solution to prevent COVID-19 that would be used daily.
COVID-19: Four B.C. groups part of Health Canada’s fight to find a treatment
April 30, 2020
The Times of Israel
Canada emerged front and center in the fight against the coronavirus on Wednesday as Health Canada approved Phase II clinical trials for a nitric oxide treatment shown to be 99% effective against COVID-19 developed by SaNOtize, an OurCrowd portfolio company based in Vancouver.
April 26, 2020
NoCamels
Vancouver-based company SaNOtize, co-founded by Israeli-Canadian scientist Dr. Gilly Regev, was granted approval by Health Canada to conduct a Phase II prevention and efficacy trial for its proposed antiviral early treatment for use against COVID-19.
April 24, 2020
The Times UK
April 22, 2020
The Globe & Mail
SaNOtize Research and Development Corp. of Vancouver, announced on Wednesday that it has received approval from Health Canada to begin a clinical trial of its method, which hinges on the delivery of nitric oxide gas to the upper-respiratory tract.
Canadian company SaNOtize Research aims to limit COVID-19 spread with nasal spray
Newswire- CISION
SaNOtize Research and Development Corporation today announced that it has been granted approval by Health Canada to conduct a multi-Centre Phase II prevention and efficacy trial for a front-line antiviral prevention and early treatment for use against COVID-19.
SaNOtize Obtains Health Canada Approval to Commence Phase II Trial for Potential COVID-19 Therapy
March 29, 2020
Read our latest Press Releases
Learn about current initiatives and updates from saNOtize.
March 18, 2020
Forbes
SaNOtize is part of a list of startups that can help defeat the coronavirus and are based in Israel or are part of the portfolios of Israeli VCs.